Ruxolitinib Plus Regorafenib

Shares of Incyte Corporation (NASDAQ: INCY) fell more than 10 percent on Thursday after the company said it will stop an ongoing Phase 2 sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP. According to Incyte's press release, the company...